CIK 0001810182
- Non-accelerated filer
- Smaller reporting company
ALX ONCOLOGY HOLDINGS INC
Sign in to watch- Ticker
- ALXO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 850642577
- Phone
- +1 650-466-7125
- Business address
- 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 7,387 shares at an average $60.88 ($449,697)
- 4 Open-market sale President & CEO sold 16,700 shares at an average $55.71 ($930,276)
- 4/A Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 7,387 shares at an average $61.97 ($457,772)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President & CEO sold 16,700 shares at an average $57.63 ($962,433)
- 4 Open-market sale Chief Medical Officer sold 7,387 shares at an average $59.43 ($438,978)
- 4 Exercise or conversion President & CEO acquired 10,000 shares (option exercise)
- 4 Open-market sale President and CEO sold 16,700 shares at an average $68.49 ($1,143,860)
- 4 Open-market sale Chief Medical Officer sold 7,387 shares at an average $74.34 ($549,173)
- 4 Exercise or conversion Chief Financial Officer acquired 6,128 shares (option exercise)
- 4 Exercise or conversion President & CEO acquired 10,000 shares (option exercise)
- 4 Open-market buy Director bought 20,000 shares at $76.00 ($1,520,000)
- 4 Open-market buy 10% owner bought 400,000 shares at $19.00 ($7,600,000)
Page 9 of 11 · 213 filings